Brii Biosciences Limited (HK:2137)
:2137
Top Page
Brii Biosciences Limited
(2137)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$1.50
▲(4.17% Upside)
Action:ReiteratedDate:10/24/25
Brii Biosciences' overall stock score is primarily impacted by its financial performance and technical analysis. The company's profitability and cash flow challenges, coupled with bearish technical indicators, significantly weigh down the score. The negative P/E ratio further contributes to a low valuation score.
Positive Factors
Strong equity and cash reserves
The balance sheet shows a strong equity position and substantial cash reserves, which provide a durable runway to fund R&D and operations over the next several months. This buffer reduces near-term liquidity pressure and supports continued clinical development and partnership execution.
Negative Factors
Consistent negative free cash flow
Sustained negative free cash flow and absence of operating cash flow in 2024 indicate structural cash generation weakness. Over 2-6 months this raises refinancing or dilution risks, limits discretionary spending on trials, and increases dependency on partners or capital markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong equity and cash reserves
The balance sheet shows a strong equity position and substantial cash reserves, which provide a durable runway to fund R&D and operations over the next several months. This buffer reduces near-term liquidity pressure and supports continued clinical development and partnership execution.
Read all positive factors
Brii Biosciences Limited (2137) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.02B
Dividend YieldN/A
Average Volume (3M)6.36M
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue GrowthN/A
EPS Growth-41.48%
CountryHK
Employees98
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding734,264,300
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)12.38
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Brii Biosciences Limited Business Overview & Revenue Model
Company Description
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patient...
How the Company Makes Money
Brii Biosciences generates revenue primarily through the development and commercialization of its therapeutic products. This includes income from partnerships and collaborations with other pharmaceutical companies, which may involve upfront paymen...
Brii Biosciences Limited Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.12M | 54.29M | 56.32M | 51.63M | 92.54M | 82.22M |
| Gross Profit | 33.12M | 54.29M | 56.32M | 51.63M | 92.54M | 82.22M |
| EBITDA | -352.36M | -392.51M | -168.20M | -503.58M | -602.80M | -890.79M |
| Net Income | -375.69M | -508.16M | -174.83M | -484.31M | -4.12B | -1.21B |
Balance Sheet | ||||||
| Total Assets | 2.49B | 2.71B | 3.20B | 3.39B | 3.61B | 1.27B |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 2.33B | 2.66B | 3.00B | 3.35B | 1.05B |
| Total Debt | 7.39M | 28.02M | 3.16M | 12.66M | 21.62M | 28.33M |
| Total Liabilities | 51.48M | 100.55M | 125.87M | 234.35M | 300.44M | 3.01B |
| Stockholders Equity | 2.49B | 2.66B | 3.12B | 3.19B | 3.34B | -1.74B |
Cash Flow | ||||||
| Free Cash Flow | -149.56M | -376.12M | -643.62M | -635.57M | -880.49M | -403.72M |
| Operating Cash Flow | -147.10M | -372.89M | -594.01M | -496.28M | -879.46M | -403.72M |
| Investing Cash Flow | 501.56M | 895.47M | -104.35M | -1.43B | -475.76M | -43.65M |
| Financing Cash Flow | -4.98M | -9.41M | -10.98M | -3.04M | 3.23B | 657.00M |
Brii Biosciences Limited Technical Analysis
Negative
1.44
Price Trends
1.48
Negative
1.55
Negative
1.75
Negative
Market Momentum
-0.03
Negative
48.23
Neutral
55.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.48, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.23 is Neutral, neither overbought nor oversold. The STOCH value of 55.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2137.
Brii Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$5.60B | -5.30 | 2.04% | ― | 1447.56% | ― | |
46 Neutral | HK$1.66B | -5.33 | -39.41% | ― | ― | 47.42% | |
43 Neutral | HK$1.02B | -4.22 | -14.48% | ― | ― | -41.48% | |
41 Neutral | HK$1.06B | -2.53 | -22.45% | ― | -8.43% | 64.33% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:2137
Brii Biosciences Limited
1.42
-0.23
-13.94%
HK:6998
Genor Biopharma Holdings Limited
2.79
0.97
53.30%
HK:1244
3D Medicines, Inc.
4.10
0.58
16.48%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.40
212.50%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.80
57.55%
HK:2511
Hightide Therapeutics Inc
3.26
1.96
150.77%
Brii Biosciences Limited Corporate Events
Brii Biosciences Updates Nomination Committee Terms
Nov 16, 2025
Brii Biosciences Limited has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. The committee’s structure and operational ...
Brii Biosciences Reports Promising Results from Phase 2 HBV Study
Nov 10, 2025
Brii Biosciences Limited has announced promising 24-week post-treatment follow-up results from Cohort 4 of its Phase 2 ENSURE study, presented at the AASLD 2025. The study evaluates a novel treatment strategy for HBV using the company’s ther...
Brii Biosciences’ Phase 2 Study Shows Promise in Hepatitis B Treatment
Nov 7, 2025
Brii Biosciences Limited announced the publication of its Phase 2 ENSURE study results in Nature Medicine, highlighting the efficacy and safety of elebsiran combined with pegylated interferon alfa (PEG-IFN α) for chronic hepatitis B treatment...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.